An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response
- PMID: 36466882
- PMCID: PMC9708728
- DOI: 10.3389/fimmu.2022.1005321
An intranasal vaccine targeting the receptor binding domain of SARS-CoV-2 elicits a protective immune response
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pathogen responsible for COVID-19, has caused an ongoing worldwide pandemic. Due to the rapid emergence of variants of concern (VOCs), novel vaccines and vaccination strategies are urgently needed. We developed an intranasal vaccine consisting of the SARS-CoV-2 receptor binding domain (RBD) fused to the antibody Fc fragment (RBD-Fc). RBD-Fc could induce strong humoral immune responses via intranasal vaccination. Notably, this immunogen could efficiently induce IgG and IgA and establish mucosal immunity in the respiratory tract. The induced antibodies could efficiently neutralize wild-type SARS-CoV-2 and currently identified SARS-CoV-2 VOCs, including the Omicron variant. In a mouse model, intranasal immunization could provide complete protection against a lethal SARS-CoV-2 challenge. Unfortunately, the limitation of our study is the small number of animals used in the immune response analysis. Our results suggest that recombinant RBD-Fc delivered via intranasal vaccination has considerable potential as a mucosal vaccine that may reduce the risk of SARS-CoV-2 infection.
Keywords: RBD-Fc; SARS-CoV-2; intranasal vaccine; mucosal immunity; mucosal vaccine.
Copyright © 2022 Chen, Zhang, Li, Wu, Zhang and Gong.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures







Similar articles
-
Mucosal IgA response elicited by intranasal immunization of Lactobacillus plantarum expressing surface-displayed RBD protein of SARS-CoV-2.Int J Biol Macromol. 2021 Nov 1;190:409-416. doi: 10.1016/j.ijbiomac.2021.08.232. Epub 2021 Sep 7. Int J Biol Macromol. 2021. PMID: 34499954 Free PMC article.
-
Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.Vaccine. 2023 May 11;41(20):3233-3246. doi: 10.1016/j.vaccine.2023.04.020. Epub 2023 Apr 14. Vaccine. 2023. PMID: 37085458 Free PMC article.
-
Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.Vaccine. 2014 Apr 11;32(18):2100-8. doi: 10.1016/j.vaccine.2014.02.004. Epub 2014 Feb 18. Vaccine. 2014. PMID: 24560617 Free PMC article.
-
Studies of SARS virus vaccines.Hong Kong Med J. 2008 Aug;14 Suppl 4:39-43. Hong Kong Med J. 2008. PMID: 18708674 Review.
-
Intranasal COVID-19 vaccines: From bench to bed.EBioMedicine. 2022 Feb;76:103841. doi: 10.1016/j.ebiom.2022.103841. Epub 2022 Jan 24. EBioMedicine. 2022. PMID: 35085851 Free PMC article. Review.
Cited by
-
Intranasal boosting with RBD-HR protein vaccine elicits robust mucosal and systemic immune responses.Genes Dis. 2023 Aug 3;11(4):101066. doi: 10.1016/j.gendis.2023.06.035. eCollection 2024 Jul. Genes Dis. 2023. PMID: 38550714 Free PMC article.
-
Intranasal Boosting with Spike Fc-RBD of Wild-Type SARS-CoV-2 Induces Neutralizing Antibodies against Omicron Subvariants and Reduces Viral Load in the Nasal Turbinate of Mice.Viruses. 2023 Mar 6;15(3):687. doi: 10.3390/v15030687. Viruses. 2023. PMID: 36992395 Free PMC article.
-
Harnessing the potential of the NALT and BALT as targets for immunomodulation using engineering strategies to enhance mucosal uptake.Front Immunol. 2024 Sep 2;15:1419527. doi: 10.3389/fimmu.2024.1419527. eCollection 2024. Front Immunol. 2024. PMID: 39286244 Free PMC article. Review.
-
Enhanced Immunogenicity and Protective Effects against SARS-CoV-2 Following Immunization with a Recombinant RBD-IgG Chimeric Protein.Vaccines (Basel). 2024 Mar 27;12(4):356. doi: 10.3390/vaccines12040356. Vaccines (Basel). 2024. PMID: 38675739 Free PMC article.
-
Intranasal influenza-vectored vaccine expressing pneumococcal surface protein A protects against Influenza and Streptococcus pneumoniae infections.NPJ Vaccines. 2024 Dec 19;9(1):246. doi: 10.1038/s41541-024-01033-5. NPJ Vaccines. 2024. PMID: 39702744 Free PMC article.
References
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous